Toxicity profile of lapatinib plus capecitabine in advanced breast cancer – a single-centre follow-up study

• Authors: Zuzanna Borysiewicz , Iwona Ryniewicz-Zander
• Languages of publication: EN

Abstracts

EN

Breast cancer is the most prevalent female neoplasm in Poland as well as in the rest of the world, accounting for 25% of all cancers. Lapatinib is a reversible inhibitor of the HER-1 and HER-2 tyrosine kinase receptors. Combined with capecitabine, it is administered in patients suffering from advanced breast cancer with HER-2 receptor overexpression. The present article analyses data obtained from medical records of 24 breast cancer patients treated with lapatinib and capecitabine in the years 2010–2015, in order to examine the treatment-related toxicity. The major adverse effects observed under treatment included diarrhoea, nausea, emesis, skin toxicity, and elevated transaminases. In 3 patients, grade 3 adverse events were reported, as assessed in accordance with CTCAE. The most frequent cause behind the cessation of treatment was disease progression. The analysis has indicated that lapatinib plus capecitabine is a well-tolerated treatment regimen.

Keywords

EN

adverse reactions; breast cancer; capecitabine; lapatinib

Discipline

• MEDICINE: MEDICINE

• Publisher: Medical Education
• Journal: OncoReview
• Year: 2015
• Volume: 5
• Issue: 4
• Pages: A164-168

Contributors

author

Zuzanna Borysiewicz

• Department of Clinical Oncology Regional Polyclinic Hospital in Elbląg, Poland

author

Iwona Ryniewicz-Zander

• Department of Clinical Oncology Regional Polyclinic Hospital in Elbląg, Poland

References

• 1. Wojciechowska U, Didkowska J, Zatoński W. Nowotwory złośliwe w Polsce w 2011 r. Centrum Onkologii, Instytut im. M. Skłodowskiej-Curie, Warszawa 2013.
• 2. Cardoso F, Harbeck N, Fallowfield L et al. Locally recurrent or metastatic breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2012; 23(suppl. 7): 11-19.
• 3. Wojtukiewicz M, Sierko E (ed.). Leczenie ukierunkowane na cele molekularne w onkologii i hematoonkologii. Via Medica, Gdańsk 2013.
• 4. Kozłowski W, Szacikowska E. Receptory HER/ERBB w prawidłowym nabłonku i kancerogenezie. Współczesna Onkologia 2000; 1: 7.
• 5. Harari P, Allen G, Bonner J et al. Biology of interactions: Antiepidermal growth factor receptor agents. J Clin Oncol 2007; 25: 4057-4065.
• 6. Geyer C, Forster J, Lindquist D, et al. Lapatynib plus capecytabine for HER-2 positive advanced breast cancer. N Eng J Med 2006; 355: 2733-2743.
• 7. Common Terminology Criteria for Adverse Events, Version 5.0, revised July 4, 2015. National Cancer Institute [online: http://ctep.cancer.gov/ protocolDevelopment/electronic_applications/ctc.htm].
• 8. Cameron D, Casey M, Oliva C et al. Lapatynib plus capecytabine in women with HER-2-positive advanced breast cancer: final survival analysis of a phase III randomized trial. The Oncologist 2010; 15: 924-934.
• 9. Crown JP, Burris HA, Boyle F et al. Pooled analysis of diarrhea events in patients with cancer treated with lapatinib. Breast Cancer Res Treat 2008; 112: 317-325.
• 10. Benson AB, Ajani JA, Catalano RB. Recommended guidelines for treatment of cancer treatment-induced diarrhea. J Clin Oncol 2004; 22: 2918-2926.
• 11. Azim HA, Agbor-Tarh D, Bradbury I et al. Pattern of rash, diarrhea and hepatic toxicities secondary to lapatinib and their association with age and response to neoadjuvant therapy: analysis from the NeoALLTO trial. J Clin Oncol 2013; 31: 4504-4511.
• 12. Lacouture ME. Mechanisms of cutaneous toxicities to EGFR inhibitors. Nat Rev Cancer 2006; 6: 803-812.
• 13. Murillas R, Larcher F, Conti CJ et al. Expression of a dominant negative mutant of epidermal growth factor receptor in the epidermis of transgenic mice elicits striking alterations in hair follicle development and skin structure. EMBO J 1995; 14: 5216-5223.
• 14. Perez-Soler R. Can rash associated with HER1/EGFR inhibition be used as a marker of treatment outcome? Oncology 2013; 17: 23-28.
• 15. Krause DS, Van Etten RA. Tyrosine kinases as targets for cancer therapy. N Engl J Med 2005; 353: 172-187.
• 16. Lacouture ME, Maitland ML, Segaert S et al. A proposed EGFR inhibitor dermatologic adverse event-specific grading scale from the MASCC skin toxicity study group. Sup Care Cancer 2010; 18: 509-522.
• 17. Laux I, Jain A, Singh S et al. Epidermal growth factor receptor dimeryzation status determines skin toxicity to HER-kinase targeted therapies. Br J Cancer 2006; 94: 85-92.

• Document Type: article